



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/194,356	09/02/1999	DARIO NERI	515-4132	3100

23599 7590 08/13/2002

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

EXAMINER

HARRIS, ALANA M

ART UNIT

PAPER NUMBER

1642

DATE MAILED: 08/13/2002

24

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

09/194,356

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
Alana M. Harris, Ph.D.	
ART UNIT	PAPER NUMBER
1642	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. Applicants submitted an amendment to the claims on May 24, 2002 as Paper number 21 encompassing the addition of new claims 30-57. The sequences contained within claim 40 and 41, line 2 have been reviewed by the Examiner. These sequences of new claims 41 and 42 have not been identified by SEQ ID numbers and accordingly are not recognized as a sequence in the sequence listing, nor a part of any of the sequences listed within the specification. Inasmuch as the amendment was entered the application still fails to comply with the requirements of the sequence rules pursuant to 37 CFR 1.821(d). Applicants must comply with sequence rules set forth in the recited section of the MPEP 2422.03 before examination can commence. Applicants' response will be held in abeyance until the application is in sequence compliance. Furthermore, neither Figure 1 or the corresponding brief description of the said figure contain identifying SEQ ID numbers. Applicants are requested to identify sequences listed in the entire application.
2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
3. Any inquiry concerning this communication should be directed to Examiner Alana M. Harris, Art Unit 1642, whose telephone number is (703)306-5880.
4. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.
5. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the

application under 37 C.F.R. § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

amtharris

Alana M. Harris, Ph.D.
Patent Examiner, Group 1642